Výsledky vyhledávání - "Aziz Ouerdani"

Akademický článek

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Autor: Neeraj Gupta, Karen L. Reckamp, David R. Camidge, Huub J. Kleijn, Aziz Ouerdani, Francesco Bellanti, John Maringwa, Michael J. Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan

Publikováno v: Clinical and Translational Science, Vol 15, Iss 5, Pp 1143-1154 (2022)

Abstract The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC). A population pharmacoki

Externí odkaz: https://doaj.org/article/c85cc577cdaa4f20a4aec707f1e3905c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections

Autor: Hwa-Ping Feng, Vincent Duval, Matthew L. Rizk, Dan Li, Carisa De Anda, Margaret Z Chou, Philip Sabato, Aziz Ouerdani, Natalya Broyde, Benjamin Guiastrennec, Pamela Sears, Catherine Hardalo

Publikováno v: Antimicrobial Agents and Chemotherapy

Tedizolid phosphate is an oxazolidinone antibacterial agent approved for the treatment of Gram-positive acute bacterial skin and skin structure infections (ABSSSIs) in patients aged ≥12 years. To support the use of tedizolid phosphate in adolescent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd357881778f3992e613ca2dee02e49
http://europepmc.org/articles/PMC8597753

Zobrazit plný text záznamu

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

Autor: Neeraj Gupta, Xiaofei Zhou, Paul M. Diderichsen, Aziz Ouerdani

Publikováno v: Journal of clinical pharmacology. 62(3)

A population pharmacokinetic (PK) analysis was conducted to characterize sources of interpatient variability on the PK of TAK-931, a cell division cycle 7 kinase inhibitor, in adult patients with advanced solid tumors using data from 198 patients who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58bbebf023e9837dfb6188ccd8bab269
https://pubmed.ncbi.nlm.nih.gov/34564871

Zobrazit plný text záznamu

Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2

Autor: Iñaki F. Trocóniz, Stéphane Goutagny, Aziz Ouerdani, Michel Kalamarides, Benjamin Ribba

Publikováno v: Cancer Chemotherapy and Pharmacology. 77:1263-1273

To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. Clinical data, including longitudinal tumor volumes in patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83675131fc0d947131e8dc16b8cfcdc9
https://doi.org/10.1007/s00280-016-3046-2

Zobrazit plný text záznamu

SIMULATED LONG-TERM EFFECTS OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY AT THE LUMBAR SPINE AS PREDICTED BY A VALIDATED SEMI-MECHANISTIC EXPOSURE-RESPONSE MODEL

Autor: Anthe S. Zandvliet, Aziz Ouerdani, Juan Camilo Arjona Ferreira, Tien-Yi Lee, Rik de Greef, Elizabeth Migoya

Publikováno v: Fertility and Sterility. 114:e350

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59b252ad216d855e8be021653a72802c
https://doi.org/10.1016/j.fertnstert.2020.08.1046

Zobrazit plný text záznamu

Population pharmacokinetic (PK) and exposure-response analyses from the pivotal ALTA-1L study: Model-based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC)

Autor: Francesco Bellanti, Michael J. Hanley, Shining Wang, Pingkuan Zhang, D. Ross Camidge, Karthik Venkatakrishnan, Aziz Ouerdani, J. Maringwa, Karen L. Reckamp, Huub Jan Kleijn, Neeraj Gupta

Publikováno v: Journal of Clinical Oncology. 38:e21725-e21725

e21725 Background: Brigatinib is a next-generation ALK tyrosine kinase inhibitor (TKI) with differential activity by dose (90 mg vs 180 mg [with a 7-day lead-in at 90 mg] qd) in the phase 2 post-crizotinib ALTA trial (NCT02094573). Herein, we describ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f39ddcfc51071b2c48238ecd30930ec
https://doi.org/10.1200/jco.2020.38.15_suppl.e21725

Zobrazit plný text záznamu

Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1

Autor: Rik de Greef, Anetta Claussen, Aziz Ouerdani, Ka Lai Yee, Larissa Wenning

Publikováno v: Antimicrobial agents and chemotherapy. 63(4)

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV-1) infection. A population pharmacokinetic (PK) model was developed for doravirine using pooled data from densely sampled pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3a7a3e77fa6fadcc3452a405b3f0fa
https://pubmed.ncbi.nlm.nih.gov/30745394

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání